Filter Results :

Your search for Neural returned 31 reports

Sort by


Postherpetic Neuralgia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

03 Nov 2016  |  Published by:  DelveInsight
SummaryDelveInsight’s, Postherpetic Neuralgia-API Insights, 2015,report provides Postherpetic Neuralgia drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by...

$ 1,250.00
$ 875.00
( Save 30% )

Read More

Postherpetic Neuralgia - Epidemiology Forecast To 2023

03 Nov 2016  |  Published by:  DelveInsight
DelveInsight Postherpetic Neuralgia - Epidemiology Forecast To 2023ť provides an overview of the epidemiology trends of Postherpetic Neuralgia in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Postherpetic Ne...

$ 2,750.00
$ 1,925.00
( Save 30% )

Read More

Acute Sensorineural Hearing Loss-Pipeline Insights, 2016

03 Nov 2016  |  Published by:  DelveInsight
Summary Acute Sensorineural Hearing Loss- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Acute Sensorineural Hearing Loss. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in...

$ 1,250.00
$ 750.00
( Save 40% )

Read More

Neuralgia-Pipeline Insights, 2016

03 Nov 2016  |  Published by:  DelveInsight
Summary Neuralgia- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Neuralgia. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Neura...

$ 1,250.00
$ 750.00
( Save 40% )

Read More

Postherpetic Neuralgia-Pipeline Insights, 2016

03 Nov 2016  |  Published by:  DelveInsight
Summary Postherpetic Neuralgia- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Postherpetic Neuralgia. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-l...

$ 1,250.00
$ 750.00
( Save 40% )

Read More

Global Neuralgia Partnering 2010-2016

01 Nov 2016  |  Published by:  CurrentPartnering
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world’s leading healthcare companies. • Trends in partnering deals • Top deals by value • Deals listed by company A-Z, industry secto...

$ 1,495.00

Read More

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2016

31 Oct 2016  |  Published by:  Global Markets Direct
Summary‘Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2016’, provides in depth analysis on Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein...

$ 3,500.00

Read More

Postherpetic Neuralgia - Pipeline Review, H2 2016

28 Sep 2016  |  Published by:  Global Markets Direct
Summary‘Postherpetic Neuralgia - Pipeline Review, H2 2016’, provides an overview of the Postherpetic Neuralgia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Postherpetic Neuralgia, complete with analysis by stage of development, drug targ...

$ 2,000.00

Read More

Neuraltus Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

20 Sep 2016  |  Published by:  GlobalData
SummaryNeuraltus Pharmaceuticals, Inc. (Neuraltus) is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of neurodegenerative diseases. The company offers products under clinical development that include NP001 and NP003. It focuses on macrophage which is base...

$ 250.00

Read More

Neuralstem, Inc. (CUR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

20 Sep 2016  |  Published by:  GlobalData
SummaryNeuralstem, Inc. (Neuralstem) is a pharmaceutical company that offers medicines for nervous system diseases. The company offers cell therapy treatment for ALS, ischemic stroke, spinal cord injury, multiple sclerosis, optic neuritis, Alzheimer's disease, traumatic brain injury, peripheral nerv...

$ 250.00

Read More

Neuralstem, Inc. (CUR) - Medical Equipment - Deals and Alliances Profile

22 Aug 2016  |  Published by:  GlobalData
SummaryNeuralstem, Inc. (Neuralstem) is a pharmaceutical company that offers medicines for nervous system diseases. The company offers cell therapy treatment for ALS, ischemic stroke, spinal cord injury, multiple sclerosis, optic neuritis, Alzheimer's disease, traumatic brain injury, peripheral nerv...

$ 250.00

Read More

Trigeminal Neuralgia Global Clinical Trials Review, H2, 2016

27 Jul 2016  |  Published by:  GlobalData
Summary"Trigeminal Neuralgia Global Clinical Trials Review, H2, 2016" provides an overview of Trigeminal Neuralgia clinical trials scenario. This report provides top line data relating to the clinical trials on Trigeminal Neuralgia. Report includes an overview of trial numbers and their average enro...

$ 2,500.00

Read More

Acute Sensorineural Hearing Loss - Pipeline Review, H2 2016

20 Jul 2016  |  Published by:  Global Markets Direct
SummaryAcute Sensorineural Hearing Loss - Pipeline Review, H2 2016, provides an overview of the Acute Sensorineural Hearing Loss pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Sensorineural Hearing Loss, complete with analysis by sta...

$ 2,000.00

Read More

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2016

22 Jun 2016  |  Published by:  Global Markets Direct
Summary‘Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2016’, provides in depth analysis on Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neura...

$ 3,500.00

Read More

Neuralstem, Inc. (CUR) - Financial and Strategic SWOT Analysis Review

15 Apr 2016  |  Published by:  GlobalData
SummaryNeuralstem, Inc. (Neuralstem) is a pharmaceutical company that develops and markets medicines based on human neural stem cell technology and cell therapy. The company provides cell therapy treatment for ALS, ischemic stroke, spinal cord injury, glioblastoma, multiple sclerosis, optic neuritis...

$ 300.00

Read More
Total 31 records.